The $1.9m grant will help the firm to develop and investigate the potential of its proprietary bioadhesive technology to improve sutured tendon repair, enhancing repair efficacy and improving patient outcomes.

Kensey Nash chief operating officer Doug Evans said the grant will enable the company to explore new applications of adhesive technology in addition to other extracellular matrix, collagen, and polymer based biomaterials to create solutions for existing medical challenges.

The company develops cardiology, endovascular, general surgery products, orthopaedic, spine and sports medicine.